Subscribe
shutterstock_1435040315_rafapress
rafapress / Shutterstock.com
18 January 2021Americas

Lawyer opposes Allergan’s bid for interlocutory appeal in FCA suit

Allergan should not be permitted to immediately appeal against a recent ruling which requires it to face allegations that it monopolised the pricing of dementia drugs, according to a New York-based patent attorney.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Judge rejects Allergan challenge to FCA suit
15 December 2020   A California judge has allowed a patent attorney to proceed with his claims against Allergan which allege the pharmaceutical company fraudulently obtained patents to monopolise pricing.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
Judge rejects Allergan challenge to FCA suit
15 December 2020   A California judge has allowed a patent attorney to proceed with his claims against Allergan which allege the pharmaceutical company fraudulently obtained patents to monopolise pricing.

More on this story

Big Pharma
Judge rejects Allergan challenge to FCA suit
15 December 2020   A California judge has allowed a patent attorney to proceed with his claims against Allergan which allege the pharmaceutical company fraudulently obtained patents to monopolise pricing.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?